ONRELTEA

This brand name is authorized in Canada

Active ingredients

The drug ONRELTEA contains one active pharmaceutical ingredient (API):

1 Brimonidine
UNII 4S9CL2DY2H - BRIMONIDINE TARTRATE

Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.

Read about Brimonidine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
D11AX21 D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AX Other dermatologicals
Discover more medicines within D11AX21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02421208

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈